CR20110324A - ANTICUERPO ANTI-cMET NOVEDOSO - Google Patents

ANTICUERPO ANTI-cMET NOVEDOSO

Info

Publication number
CR20110324A
CR20110324A CR20110324A CR20110324A CR20110324A CR 20110324 A CR20110324 A CR 20110324A CR 20110324 A CR20110324 A CR 20110324A CR 20110324 A CR20110324 A CR 20110324A CR 20110324 A CR20110324 A CR 20110324A
Authority
CR
Costa Rica
Prior art keywords
cmet
new antibody
liposomes
antibody
new
Prior art date
Application number
CR20110324A
Other languages
English (en)
Inventor
Liliane Goetsch
Thierry Wurch
Cedric Bes
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110324(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of CR20110324A publication Critical patent/CR20110324A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Connection Of Motors, Electrical Generators, Mechanical Devices, And The Like (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una composicion de liposoma que comprende liposomas con un compuesto inhibidor de la proteasoma con péptido de ácido borónico atrapado en los liposomas.
CR20110324A 2008-12-02 2011-06-13 ANTICUERPO ANTI-cMET NOVEDOSO CR20110324A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2008/055663 WO2010064089A1 (en) 2008-12-02 2008-12-02 Novel anti-cmet antibody
US18450209P 2009-06-05 2009-06-05

Publications (1)

Publication Number Publication Date
CR20110324A true CR20110324A (es) 2011-07-28

Family

ID=41693124

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110324A CR20110324A (es) 2008-12-02 2011-06-13 ANTICUERPO ANTI-cMET NOVEDOSO

Country Status (38)

Country Link
US (4) US8741290B2 (es)
EP (4) EP3757132A1 (es)
JP (3) JP5863458B2 (es)
KR (1) KR101838299B1 (es)
CN (2) CN102227446B (es)
AR (1) AR074439A1 (es)
AU (3) AU2009328318C1 (es)
BR (2) BR122019023930B1 (es)
CA (1) CA2743433C (es)
CL (2) CL2011001296A1 (es)
CO (1) CO6382139A2 (es)
CR (1) CR20110324A (es)
CY (2) CY1119172T1 (es)
DK (2) DK3135691T3 (es)
EC (1) ECSP11011127A (es)
ES (3) ES2827277T3 (es)
GE (2) GEP20135930B (es)
HR (2) HRP20171011T8 (es)
HU (3) HUE040553T2 (es)
IL (2) IL213273A0 (es)
LT (2) LT3135691T (es)
MA (1) MA32892B1 (es)
MX (2) MX2011005677A (es)
MY (2) MY192567A (es)
NZ (1) NZ593853A (es)
PE (1) PE20120343A1 (es)
PH (1) PH12015501515A1 (es)
PL (3) PL3135691T3 (es)
PT (3) PT3135691T (es)
RS (2) RS56204B1 (es)
RU (2) RU2015127471A (es)
SA (2) SA109300720B1 (es)
SG (2) SG171851A1 (es)
SI (3) SI3135691T1 (es)
TN (1) TN2011000216A1 (es)
TW (2) TWI459964B (es)
WO (1) WO2010069765A1 (es)
ZA (1) ZA201105164B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
KR20140019284A (ko) 2010-09-03 2014-02-14 아카데미아 시니카 항-C-Met 항체 및 이의 이용 방법들
EP2635602B1 (en) 2010-11-03 2016-09-07 Argen-X Nv Anti c-met antibodies
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
KR101865223B1 (ko) 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
KR101463098B1 (ko) 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
WO2013192594A2 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
EP2992019B1 (en) 2013-04-30 2019-03-06 Agency For Science, Technology And Research Mab 2 anti-met antibody
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
ES2729797T3 (es) * 2013-12-20 2019-11-06 Dev Ct Biotechnology Anticuerpos específicos de la alfa-enolasa y métodos de uso en terapias contra el cáncer
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CN107613974B (zh) 2015-03-16 2021-01-15 塞尔德克斯医疗公司 抗-met抗体及其使用方法
JP6669882B2 (ja) * 2016-02-05 2020-03-18 ヘリックスミス カンパニー リミテッド 抗−ｃ−ＭＥＴ抗体及びその用途
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
RS61659B1 (sr) * 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
WO2018088933A1 (en) * 2016-11-14 2018-05-17 Limited Liability Company "Panacela Labs" Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018129029A1 (en) * 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109771642B (zh) 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US12378318B2 (en) * 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
CN113874392B (zh) * 2019-03-28 2025-10-21 丹尼斯科美国公司 工程化抗体
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
EP4129335A4 (en) 2020-09-01 2024-04-24 RemeGen Co., Ltd. ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CA3214989A1 (en) 2021-04-06 2022-10-13 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin
CN117157325A (zh) * 2021-04-08 2023-12-01 拜奥迪斯私人有限公司 抗c-met抗体和抗体-药物缀合物
TW202547842A (zh) 2021-04-29 2025-12-16 愛爾蘭商艾伯維製造管理無限公司 抗c-Met抗體藥物結合物
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
US20230285394A1 (en) 2022-03-11 2023-09-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib
IL324585A (en) 2023-05-23 2026-01-01 Abbvie Mfg Management Unlimited Company Methods of treatment using anti-c-met antibody drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
WO2002055106A2 (en) * 2001-01-09 2002-07-18 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
WO2004072117A2 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US20050233960A1 (en) * 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
EP1773885B1 (en) 2004-08-05 2010-04-21 Genentech, Inc. Humanized anti-cmet antagonists
WO2006116260A2 (en) * 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
AU2006270009A1 (en) * 2005-07-18 2007-01-25 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
WO2007016285A2 (en) * 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
EP2004693B1 (en) * 2006-03-30 2012-06-06 Novartis AG Compositions and methods of use for antibodies of c-met
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
ECSP11011127A (es) 2011-07-29
AU2009328318A1 (en) 2011-07-28
US8729249B2 (en) 2014-05-20
JP2016117721A (ja) 2016-06-30
CA2743433A1 (en) 2010-06-24
EP2370468B1 (en) 2017-04-05
MA32892B1 (fr) 2011-12-01
BRPI0923231B1 (pt) 2020-04-28
PE20120343A1 (es) 2012-04-16
US8741290B2 (en) 2014-06-03
HRP20181868T1 (hr) 2019-01-11
RU2015127471A (ru) 2018-12-21
AU2016200725C1 (en) 2017-10-19
HRP20171011T1 (hr) 2017-09-22
PT3431502T (pt) 2020-10-29
MX2011005677A (es) 2011-06-30
EP3135691A1 (en) 2017-03-01
WO2010069765A1 (en) 2010-06-24
MX341014B (es) 2016-08-03
AU2017203929A1 (en) 2017-07-06
EP3135691B1 (en) 2018-08-15
HK1162536A1 (zh) 2012-08-31
TW201446805A (zh) 2014-12-16
ES2697098T3 (es) 2019-01-22
RU2560257C2 (ru) 2015-08-20
NZ593853A (en) 2013-03-28
HUE040553T2 (hu) 2019-03-28
RS58018B1 (sr) 2019-02-28
MY192567A (en) 2022-08-29
CO6382139A2 (es) 2012-02-15
US20130109841A1 (en) 2013-05-02
HUE035047T2 (en) 2018-05-02
CN102227446B (zh) 2015-10-21
PL2370468T3 (pl) 2017-09-29
DK3135691T3 (en) 2018-11-19
CN102227446A (zh) 2011-10-26
SA109300720B1 (ar) 2013-05-25
TWI523866B (zh) 2016-03-01
JP2017099392A (ja) 2017-06-08
EP2370468A1 (en) 2011-10-05
BRPI0923231A2 (pt) 2016-01-26
SI3431502T1 (sl) 2021-01-29
GEP20146207B (en) 2014-12-10
MY185200A (en) 2021-04-30
AU2009328318C1 (en) 2017-11-02
EP3431502B1 (en) 2020-07-22
AR074439A1 (es) 2011-01-19
DK2370468T3 (en) 2017-06-19
PT2370468T (pt) 2017-07-13
HUE051288T2 (hu) 2021-03-01
CA2743433C (en) 2019-06-11
AU2017203929B2 (en) 2019-03-28
TW201023892A (en) 2010-07-01
RU2011124751A (ru) 2013-01-10
RS56204B1 (sr) 2017-11-30
SI3135691T1 (sl) 2018-12-31
PT3135691T (pt) 2018-11-27
TN2011000216A1 (en) 2012-12-17
ZA201105164B (en) 2012-03-28
BR122019023930B1 (pt) 2021-05-04
CY1121025T1 (el) 2019-12-11
ES2629855T3 (es) 2017-08-16
SG171851A1 (en) 2011-07-28
LT2370468T (lt) 2017-07-10
AU2009328318B2 (en) 2015-11-05
JP5863458B2 (ja) 2016-02-16
BRPI0923231B8 (pt) 2021-05-25
CN103351438B (zh) 2016-04-20
CL2011001296A1 (es) 2011-08-26
US20110239316A1 (en) 2011-09-29
ES2827277T3 (es) 2021-05-20
JP6074018B2 (ja) 2017-02-01
EP3757132A1 (en) 2020-12-30
PL3135691T3 (pl) 2019-02-28
IL231525A0 (en) 2014-04-30
KR20110097839A (ko) 2011-08-31
PH12015501515A1 (en) 2015-12-14
AU2016200725A1 (en) 2016-02-25
LT3135691T (lt) 2018-11-12
TWI459964B (zh) 2014-11-11
GEP20135930B (en) 2013-10-10
PL3431502T3 (pl) 2020-12-28
SA112331005B1 (ar) 2015-09-13
HK1190414A1 (zh) 2014-07-04
CY1119172T1 (el) 2018-02-14
HRP20171011T8 (hr) 2019-01-25
IL213273A0 (en) 2011-07-31
JP2012510280A (ja) 2012-05-10
US20130109840A1 (en) 2013-05-02
JP6309657B2 (ja) 2018-04-11
EP3431502A1 (en) 2019-01-23
CN103351438A (zh) 2013-10-16
AU2016200725B2 (en) 2017-05-25
IL231525B (en) 2019-07-31
KR101838299B1 (ko) 2018-03-14
US8747850B2 (en) 2014-06-10
SG187518A1 (en) 2013-02-28
US8765128B2 (en) 2014-07-01
SI2370468T1 (sl) 2017-08-31
US20130109844A1 (en) 2013-05-02
CL2014000181A1 (es) 2014-07-25

Similar Documents

Publication Publication Date Title
CR20110324A (es) ANTICUERPO ANTI-cMET NOVEDOSO
CL2012002741A1 (es) Metodo para determinar en una muestra de sangre la presencia de vitamina d libre; inmunoensayo para detrminar presencia de vitamina d libre en sangre; kit para efectuar inmunoensayo.
ES2629749T3 (es) Inmunidad tumoral
AR114921A2 (es) Método para preparar 2-amino-n-(2,2,2-trifluoroetil)acetamida
DOP2009000230A (es) Detergente liquido con particula refractiva
WO2011140353A3 (en) Remote phosphor tape for lighting units
WO2013002509A3 (ko) 새로운 화합물 및 이를 이용한 유기 발광 소자
DK2719388T3 (da) Borholdige små molekyler som antiinflammatoriske midler
AR063220A1 (es) Composicion para cementar que comprende un cemento no reaccionado
ATE541975T1 (de) Lichtemittierender getufteter teppich
WO2012077902A3 (ko) 유기광전자소자용 화합물, 이를 포함하는 유기발광소자 및 상기 유기발광소자를 포함하는 표시장치
AR094077A1 (es) Composiciones de dos componentes que contienen complejos de haluro de zinc tetrabasico - aminoacido y cisteina
CL2007002615A1 (es) Metodos para aislar o purificar un producto que comprende poner el producto enlazado en contacto con al menos una solucion de lavado que comprende arginina y luego eluir el producto; y dicho producto.
MX2010004731A (es) Dispositivos fotovoltaicos que incluyen peliculas semiconductoras impurificadas.
GT200500269A (es) Procedimiento
MX2009005179A (es) Un metodo para derivar cabello con un polietilenglicol reactivo.
ES2530578T3 (es) Cristales y cristales reticulados de Proteína A y métodos de uso de los mismos
CL2012003185A1 (es) Formulacion farmaceutica en forma de comprimidos que comprenden una primera fase que contiene irbesartan y una segunda fase que contiene un inhibidor de hmg-coa reductasa y un aditivo alcalino; metodo de preparacion de la formulacion farmaceutica.
CL2011000098A1 (es) Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.
TWD156604S (zh) 照明設備
CR11859A (es) Composición y proceso-356
EP2126744A4 (en) IDENTIFYING EXECUTABLE SCENARIO SOLUTIONS AS AN ANSWER TO SEARCH QUESTIONS
AR074627A1 (es) Resinas de melamina urea formaldehido estables durante el almacenamiento y aplicaciones de las mismas
CR7815S (es) Botella
AR093738A1 (es) Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos